Contineum Therapeutics
CTNM
62 hedge funds and large institutions have $206M invested in Contineum Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 22 closing their positions.
11,500% more call options, than puts
Call options by funds: $232K | Put options by funds: $2K
271% more capital invested
Capital invested by funds: $55.4M → $206M (+$150M)
8.42% more ownership
Funds ownership: 72.53% → 80.95% (+8.4%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
11% less funds holding
Funds holding: 70 → 62 (-8)
36% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$17.1M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.67M |
| 3 |
Millennium Management
New York
|
+$4.14M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.78M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$1.89M |
| 2 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$1.27M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.17M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$716K |
| 5 |
Squarepoint
New York
|
-$615K |
CTNM Hedge Fund Activity: Q3 2025 in Review
62 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q3 2025, worth a combined $206M — up 271% from $55.4M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CTNM and 14 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 18 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $17.1M. The largest seller was Baker Bros. Advisors, cutting an estimated $1.89M.
- 62 institutional investors held Contineum Therapeutics (CTNM) as of Q3 2025, down from 70 in Q2 2025.
- Funds reported $206M of Contineum Therapeutics stock for Q3 2025, up 271% quarter-over-quarter.
- 14 funds opened new Contineum Therapeutics positions in Q3 2025 and 22 closed out, a net change of -8 holders.
- The largest Contineum Therapeutics buyer in Q3 2025 was RA Capital Management, an estimated $17.1M added.
- The largest Contineum Therapeutics seller in Q3 2025 was Baker Bros. Advisors, an estimated $1.89M sold.
Based on aggregated 13F filings for Q3 2025.